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of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell
Transplantation for Multiple Myeloma or Malignant Lymphoma
Original Article
Purpose
Although hepatitis B surface antigen (HBsAg)–negative, hepatitis B core antibody (anti-HBc)–
negative patients are not considered to be at risk for hepatitis B virus (HBV)–related hepa-
titis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of
HBV-related hepatitis in HBsAg-negative, anti-HBc–negative patients receiving autologous
stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. 
Materials and Methods
We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc–negative
and 110 anti-HBc–positive at the time of ASCT) who received ASCT for MM or lymphoma.
The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV
serology results at the time of ASCT were compared with those at the time of diagnosis of
MM or lymphoma. 
Results
Three patients (two anti-HBc–negative MMs and one anti-HBc–positive MM) developed
HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among 
patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently
occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients
(16.7% with MM and 5.4% with lymphoma) who were HBsAg–negative and anti-HBc–pos-
itive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. 
Conclusion
Our data suggest that HBsAg-negative, anti-HBc–negative patients at the time of ASCT for
MM or lymphoma still might be at a risk for HBV-related hepatitis.
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Introduction
Hepatitis B virus (HBV)–related hepatitis is a serious com-
plication resulting from HBV reactivation after immunosup-
pressive treatment in patients with resolved HBV. Resolved
HBV infections are usually defined as hepatitis B surface
antigen (HBsAg)–negative and hepatitis B core antibody
(anti-HBc)–positive status in individuals with low (< 200
IU/mL) or undetectable levels of HBV-DNA [1-3]. Patients
who are HBsAg-negative and anti-HBc–negative are often
classified as HBV naïve [1] and are not considered to be at a
risk of developing HBV-related hepatitis in clinical practice.
Autologous stem cell transplantation (ASCT) is an effective
approach for the treatment of multiple myeloma (MM) and
malignant lymphoma. However, MM and lymphoma are
known to increase the risk of HBV reactivation [4-6]. There-
fore, HBV-related hepatitis following HBV reactivation is an
important clinical concern in MM and lymphoma patients
with resolved HBV during or after ASCT. To prevent HBV-
related hepatitis, all patients with MM or lymphoma should
be screened for HBsAg and anti-HBc prior to ASCT [3,7,8].
HBV prophylaxis or HBV pre-emptive therapy according to
HBV-DNA results are recommended in HBsAg-negative,
anti-HBc–positive patients by the European Association for
the Study of the Liver (EASL) Clinical Practice Guidelines,
although the American Association for the Study of Liver
Diseases (AASLD) Practice Guidelines do not recommend
routine HBV prophylaxis for these patients [3,7]. In HBsAg-
negative, anti-HBc–negative patients, however, no guide-
lines suggest that these patients should be evaluated for the
risk of HBV-related hepatitis. Nevertheless, HBsAg-negative,
anti-HBc–negative patients prior to ASCT might still be at
risk of developing HBV-related hepatitis: For instance, 
although anti-HBc is generally known to persist throughout
one’s lifetime, impaired production of anti-HBc can occur
during chemotherapy prior to ASCT in patients who are
HBsAg-negative and anti-HBc–positive at the time of diag-
nosis of MM or lymphoma [9]. This may result in erro-
neously interpreting a patient’s HBV infection status at the
time of ASCT as HBV-naïve if there is no known previous 
information. However, to our knowledge, the risk of HBV-
related hepatitis in patients who are HBsAg-negative and
anti-HBc–negative has not been reported, and tends to be 
underestimated by physicians. Hence, we conducted this ret-
rospective study to clarify the risk of HBV-related hepatitis
in patients who are HBsAg-negative and anti-HBc–negative
at the time of ASCT for MM or lymphoma.
Materials and Methods
1. Patients and study design
Two hundred eighty-eight patients who were diagnosed
with MM or malignant lymphoma received ASCT at Sever-
ance Hospital, Seoul, Korea between November 2005 and
April 2014. All patients were tested for serologic markers of
HBV prior to ASCT as a baseline. Among them, HBsAg-neg-
ative patients were enrolled in this study retrospectively. 
Patients who were not tested for anti-HBc at baseline were
excluded (Fig. 1). Patients with HBsAg–negativity were not
tested for HBV-DNA levels and did not receive anti-HBV
agents, because reimbursement guidelines set by the Korean
government did not permit such testing and treatment in
these patients. We then analyzed the rates of HBV-related
hepatitis after ASCT according to baseline anti-HBc status.
As reconstitution of normal humoral and cellular immunity
after ASCT may require 1 year or more [10], we considered
HBV-related hepatitis that occurred within and more than 1
year after ASCT as early and delayed events, respectively.
Next, the results on serologic markers of HBV at baseline
were compared to those at the time of diagnosis of MM or
lymphoma. Additionally, we also assessed the potential 
impact of rituximab on changes in HBV serology in lym-
phoma patients in sub-analysis.
2. Definitions of hepatitis, HBV-related hepatitis, and
HBV-related death
Hepatitis was defined as a threefold or greater increase in
serum alanine transaminase (ALT) levels that exceeded the
reference range (5.0-46.0 U/L) or an absolute increase in ALT
to greater than 100 U/L [11]. HBV reactivation is usually 
defined as the appearance of HBV-DNA or a more than 
10-fold increase in serum HBV-DNA than that at baseline
[1,2]. As serum HBV-DNA was not tested regularly, unless
positive conversion of HBsAg (HBsAg reversion) was noted,
HBV reactivation could not be identified. Therefore, we 
defined hepatitis attributed to HBV (HBV-related hepatitis)
as the presence of HBsAg reversion with no clinical or labo-
ratory features of acute infection with acute hepatitis A or C,
any other systemic infection, or drug-induced hepatitis. The
definition of HBV-related death was defined as any death 
resulting from HBV-related hepatitis.
3. Determination of hepatitis and HBV-related hepatitis
after ASCT
After ASCT, liver function tests were conducted every 2
weeks for 3 months and monthly thereafter for at least 2
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years. HBV serologic markers were tested if HBV-related
hepatitis was clinically suspected. Serum HBV-DNA levels
were measured if HBsAg reversion was detected. Serum
HBV-DNA levels were quantified with a real-time poly-
merase chain reaction assay on a Cobas TaqMan 48 analyzer
(Roche Molecular Systems, Branchburg, NJ). The lower 
detection limit was 60 copies/mL.
4. Statistical analysis
Frequencies between groups were evaluated and com-
pared using chi-square or Fisher exact tests. Mann-Whitney
U tests were applied for continuous variables. A binary 
logistic regression test was applied for multivariate analysis.
Two-tailed p-values less than 0.05 were considered signifi-
cant. All statistical analyses were performed using SPSS soft-
ware ver. 20.0 (IBM Corp., Armonk, NY).
5. Ethical statement
The present study conformed to the ethical guidelines of
the World Medical Association Declaration of Helsinki and
was approved by the Institutional Review Board of Sever-
ance Hospital (IRB approval number: 4-2014-0958). Informed
consent was waived because the study was based on retro-
spective review of clinical data.
Results
1. Patient characteristics
Of the 288 patients who were initially screened, 274 were
HBsAg-negative. Of these, three patients were not tested for
anti-HBc at the time of ASCT and excluded from this study
(Fig. 1). The baseline characteristics of the remaining 271 
patients are summarized in Table 1. Information on previous
vaccinations could not be obtained. Most of the baseline fac-
tors were not significantly different between groups with or
without anti-HBc, except for gender, age, and hepatitis B sur-
face antibody (anti-HBs) positivity. The most common sub-
type of malignant lymphoma was diffuse large B-cell
lymphoma (DLBCL; n=96, 54.2%). The median follow-up 
duration was 683 days (range, 8 to 3,147 days) from the date
of ASCT.
Hyunsung Park, HBV-Related Hepatitis after ASCT
Fig. 1. The incidence of hepatitis and hepatitis B surface antigen (HBsAg) reversion in 271 HBsAg-negative patients within
and more than 1 year after autologous stem cell transplantation without hepatitis B virus (HBV) prophylaxis. Anti-HBc, hep-
atitis B core antibody; Anti-HBs, hepatitis B surface antibody; ASCT, autologous stem cell transplantation.
Anti-HBc unknown
at ASCT (n=3)
Anti-HBs–positive
at ASCT (n=114, 100%)
Anti-HBs–negative
at ASCT (n=47, 100%)
Anti-HBs–positive
at ASCT (n=93, 100%)
Anti-HBs–negative
at ASCT (n=17, 100%)
HBsAg-negative, anti-HBc–negative
at ASCT (n=161)
HBsAg-negative, anti-HBc–positive
at ASCT (n=110)
HBsAg–positive
at ASCT (n=14)
Screening at ASCT (n=288)
No HBsAg reversion within 1 year after ASCT
HBsAg reversion more
than 1 year after ASCT
(n=2, 1.8%)
HBsAg reversion more
than 1 year after ASCT
(n=1, 2.1%)
HBsAg reversion more
than 1 year after ASCT
(n=1, 1.1%)
HBsAg reversion more
than 1 year after ASCT
(n=0, 0%)
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2. Hepatitis, HBV-related hepatitis, and HBV-related death
after ASCT
Among the 271 enrolled patients, 161 were anti-HBc–neg-
ative and 110 were anti-HBc–positive at baseline (Fig. 1).
Within 1 year after ASCT, 71 of the anti-HBc–negative 
patients and 48 of the anti-HBc–positive patients experienced
hepatitis (44.1% vs. 43.6%, p > 0.999). Neither HBsAg rever-
sion nor HBV-related hepatitis was recorded within 1 year
after ASCT, regardless of anti-HBc and anti-HBs status in
both groups (Fig. 1). However, two anti-HBc–negative 
patients (1.2%) and one anti-HBc–positive patient (0.9%) 
developed HBV-related hepatitis at days 406, 457, and 763
after ASCT, respectively (Table 2). One of these patients died
of HBV-related hepatitis. One lymphoma patient with anti-
HBc–negative showed HBsAg reversion without hepatitis at
day 1,172 after ASCT. The rate of delayed HBV-related hep-
atitis did not differ between patients with and without anti-
HBc after adjustment for anti-HBs positivity (p=0.843).
Anti-HBs positivity also did not affect the rate of delayed
HBV-related hepatitis after adjustment for anti-HBc status
(p=0.710). Delayed HBV-related hepatitis occurred more fre-
quently in MM patients (3 of 94, 3.2%) than in lymphoma 
patients (0 of 177, 0%; p=0.041).
3. Clinical characteristics of four patients with HBsAg 
reversion after ASCT
Clinical characteristics of the four patients who experi-
enced HBsAg reversion are listed in Table 2. Patient 1 (MM,
anti-HBc–positive) received ASCT, with hematologic disease
progression detected at day 98 after ASCT. HBV-related hep-
atitis developed at day 763 after ASCT; however, liver func-
tion improved without the need for anti-HBV therapy.
Patient 2 (MM) exhibited anti-HBc positivity at the time of
MM diagnosis; however, the patient became anti-HBc nega-
tive at the time of ASCT. Relapse of MM occurred at day 337
after ASCT, and HBV-related hepatitis developed at day 406
after ASCT, with HBV-DNA levels of 47,600 IU/mL. Ente-
cavir 0.5 mg daily was administered. In spite of anti-HBV
therapy, however, the patient died from hepatic failure at
day 453 after ASCT. Patient 3 (MM, anti-HBc–negative) 
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Characteristic Anti-HBc (+) Anti-HBc (–) p-valueat ASCT at ASCT
No. of patients 110 (40.6) 161 (59.4)
Male/Female 72/38 81/80 0.018 
Age at ASCT (yr) 53 (16-65) 48 (17-65) 0.001 
Anti-HBs positive 93 (84.5) 114 (70.8) 0.009 
MM/Lymphoma 38/72 56/105 NS 
Pre-ASCT status 
No. with elevated ALT 5 ( 8 ( NS 
ALT (U/L) 19 (3-59) 15 (3-129) 0.122 
Total bilirubin (mg/dL) 0.4 (0.2-1.1) 0.4 (0.2-1.9) 0.323 
Albumin (g/dL) 4.1 (2.7-5.3) 4.0 (1.2-5.5) 0.683 
LDH (U/L) 247.5 (107-797) 266 (94-2,162) 0.299 
Interval from diagnosis to ASCT (day) 212 (39-2,891) 217 (70-5,230) 0.503 
Cycles of CTx before ASCT 7.0 (0-36) 7.0 (3-43) 0.477 
MM 4.0 (0-19) 5.0 (3-43)
Lymphoma 7.0 (3-36) 7.0 (3-19)
Lines of CTx before ASCT 1.0 (0-4) 2.0 (1-6) 0.070 
Conditioning regimens 
Melphalan-based in MM patients 38 (100) 56 (100) NA 
Busulfan-based in lymphoma patients 64 (88.9) 82 (78.1) 0.072 
Previous rituximab therapy 37 (33.6) 53 (32.9) NS 
Interval from last use of rituximab to ASCT (day) 71 (0-1,299) 92 (6-2,869) 0.427 
Table 1. Baseline characteristics according to anti-HBc status in HBsAg-negative patients prior to ASCT
Values are presented as number (%) or median (range). Anti-HBc, hepatitis B core antibody; HBsAg, hepatitis B surface antigen;
ASCT, autologous stem cell transplantation; Anti-HBs, hepatitis B surface antibody; MM, multiple myeloma; NS, not signifi-
cant; ALT, alanine transaminase; LDH, lactate dehydrogenase; CTx, chemotherapy; NA, not available.
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developed HBV-related hepatitis at day 457 after ASCT, dur-
ing maintenance therapy with thalidomide and pred-
nisolone. Tenofovir 300 mg daily was administered, and the
patient’s HBV-DNA titers became undetectable. Patient 4,
who had primary DLBCL of the central nervous system (anti-
HBc–negative), did not receive any chemotherapy after
ASCT. HBsAg reversion without hepatitis was incidentally
detected at day 1,172 after ASCT. The status of anti-HBc at
the time of diagnosis of MM or lymphoma in patients 3 and
4 could not be identified.
4. Changes in HBV serologic markers from diagnosis to
transplantation
Among the 271 HBsAg-negative patients at baseline, 124
were tested for anti-HBc at the time of diagnosis of MM or
lymphoma (Fig. 2A). Among them, 55 patients (44.4%) were
anti-HBc–positive and 69 (55.6%) were anti-HBc–negative.
Of the 55 anti-HBc–positive patients, 50 (90.9%) maintained
their anti-HBc positivity. However, five patients (9.1%, two
lymphomas and three MMs) lost anti-HBc positivity during
chemotherapy (median cycles of chemotherapy: seven 
cycles) and showed negativity for anti-HBc at the time of
ASCT. The two lymphoma patients who lost anti-HBc posi-
tivity had received rituximab-containing chemotherapy. The
disappearance rate of anti-HBc during chemotherapy was
16.7% in MM patients (median cycles of chemotherapy: four
cycles) and 5.4% in lymphoma patients (median cycles of
chemotherapy: seven cycles), although the difference was not
statistically significant (p=0.317) (Table 3). Rituximab-con-
taining chemotherapy did not significantly affect the disap-
pearance rate of anti-HBc in lymphoma patients (p=0.230)
(Table 3).
Among the 208 patients who were HBsAg-negative at the
time of ASCT and tested for anti-HBs at the time of diagnosis
of MM or lymphoma, 128 (61.5%) were anti-HBs–positive
and 80 (38.5%) were anti-HBs–negative at the time of diag-
nosis (Fig. 2B). Of the 128 anti-HBs–positive patients, 12
Hyunsung Park, HBV-Related Hepatitis after ASCT
Table 2.  Clinical characteristics of four patients with HBsAg reversion after ASCT
Patient 1 Patient 2 Patient 3 Patient 4
At the time of ASCT
Age 60 54 54 46
Sex Male Male Male Female
Diagnosis MM MM MM DLBCL
Previous lines of CTx 4 2 2 1
Prior use of rituximab No No No No
HBV serology at diagnosisa) –/NA/NA –/+/– –/NA/NA –/NA/+
HBV serology at ASCTa) –/+/+ –/–/– –/–/+ –/–/+
Anti-HBs titer (IU/L) 11.67 9.76 44.40 42.65
HBV-DNA (IU/mL) NA NA NA NA
ALT (U/L) 12 6 10 12
Conditioning regimen HD Mel VelBuMel HD Mel BuTT
HBV prophylaxis ND ND ND ND
CTx after ASCT Steroid only Thal, steroid, DCEP Thal, steroid ND
At the time of HBsAg reversion
HBV serologya) +/+/– +/+/– +/NA/– +/NA/–
No. of days after ASCT 763 406 457 1,172
HBV-DNA (IU/mL) 91,700,000 47,600 2,200,000 NA
Peak ALT (U/L) 103 3,163 424 34
Peak total bilirubin (mg/dL) 0.6 22.2 4.0 0.5
HBV treatment No Entecavir Tenofovir No
Outcomes Alive and well Died of hepatic failure Alive and well Alive and well
HBsAg, hepatitis B surface antigen; ASCT, autologous stem cell transplantation; MM, multiple myeloma; DLBCL, diffuse
large B-cell lymphoma; CTx, chemotherapy; NA, not available; Anti-HBs, hepatitis B surface antibody; HBV, hepatitis B virus;
ALT, alanine transaminase; HD Mel, high-dose melphalan; VelBuMel, bortezomib, busulfan and melphalan; BuTT, busulfan
and thiotepa; ND, not done; Thal, thalidomide; DCEP, dexamethasone, cyclophosphamide, etoposide and cisplatin; Anti-
HBc, hepatitis B core antibody. a)HBsAg/anti-HBc/anti-HBs.
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(9.4%) lost anti-HBs positivity during a median of seven 
cycles of chemotherapy and showed negativity for anti-HBs
at the time of ASCT. The disappearance rate of anti-HBs dur-
ing chemotherapy was significantly higher in MM patients
(25.0%; median cycles of chemotherapy, four cycles) than in
lymphoma patients (4.2%; median cycles of chemotherapy,
seven cycles) (p=0.002) (Table 3). Rituximab-containing
chemotherapy did not significantly affect the rate of anti-HBs
disappearance in lymphoma patients (p=0.347) (Table 3).
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Fig. 2. Changes in hepatitis B core antibody (anti-HBc) status (A) and hepatitis B surface antibody (anti-HBs) status (B) in
hepatitis B surface antigen (HBsAg)–negative patients from diagnosis to transplantation. ASCT, autologous stem cell trans-
plantation.
At transplantation
Chemotherapy
median 7 cycles
HBsAg-negative
at ASCT (n=271)
Anti-HBc tested
at diagnosis (n=124)
Anti-HBc not tested
at diagnosis (n=147)
HBsAg-negative
Anti-HBc–positive at diagnosis
(n=55, 100%)
HBsAg-negative
Anti-HBc–positive
(n=50, 90.9%)
HBsAg-negative
Anti-HBc–negative
(n=5, 9.1%)
HBsAg-negative
Anti-HBc–positive
(n=1, 1.4%)
HBsAg-negative
Anti-HBc–negative
(n=68, 98.6%)
HBsAg-negative
Anti-HBc–negative at diagnosis
(n=69, 100%)
At diagnosis
A
At transplantation
Chemotherapy
median 7 cycles
At diagnosis
HBsAg-negative
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HBsAg-negative
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B
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Discussion
Anti-HBc is generally the most reliable serological marker
of remote HBV infection [12]. However, in the present study,
we found that 9.1% of MM and lymphoma patients experi-
enced negative conversion of anti-HBc at the time of ASCT
and remained at risk for HBV-related hepatitis. Accordingly,
we suggest that HBsAg-negative, anti-HBc–negative patients
at the time of ASCT should not be considered as HBV naïve,
particularly if there is not sufficient information on previous
HBV infection. Considering that the rate of anti-HBc positiv-
ity alone is higher in areas with a high prevalence of HBV 
infection [13], the risk of HBV-related hepatitis in HBsAg-
negative, anti-HBc–negative patients may theoretically be
proportional to the area’s prevalence of HBV infections.
HBV-related hepatitis following HBV reactivation in 
patients with resolved HBV is an emerging concern during
intensive chemotherapy. Several studies have evaluated the
risk of developing HBV-related hepatitis in patients with
HBV infection who have received intensive chemotherapy
[11,14,15]. However, most of these previous studies have pri-
marily focused on patients with resolved HBV infection 
defined as HBsAg negativity and anti-HBc positivity. Indeed,
guidelines from the AASLD [3], EASL [7], and Asian-Pacific
consensus statement [8] recommend that screening tests for
HBsAg and anti-HBc in patients who are at risk of HBV 
infection should be performed before initiation of cytotoxic
chemotherapy and that HBV-DNA should be monitored 
periodically in HBsAg-negative, anti-HBc–positive patients.
Although these criteria may be useful before immunosup-
pressive therapy or chemotherapy, they may not be enough
to determine whether patients are at risk for HBV-related
hepatitis at the time of ASCT. As shown in our study, which
was conducted in Korea where the prevalence of HBV infec-
tion and anti-HBc positivity alone is high [16], a considerable
number of patients with MM or lymphoma lost anti-HBc
positivity during chemotherapy; moreover, the rate of HBV-
related hepatitis did not differ between patients who were
anti-HBc–negative and those who were anti-HBc–positive
prior to undergoing ASCT. Our finding of a relatively low
rate of HBV-related hepatitis in anti-HBc–positive patients
may be due in part to the relatively short follow-up duration
of our study (median, 683 days) because a recent study sug-
gested that most HBV reactivations occur more than 19
months after transplantation [17]. Nevertheless, our data
suggest that the risk of HBV-related hepatitis in HBsAg-neg-
ative, anti-HBc–negative patients at the time of ASCT is not
negligible, particularly in HBV endemic areas, such as South-
East Asia and Western Pacific Regions [18].
Notably, the absolute percentage of patients who lost anti-
HBc during chemotherapy prior to ASCT was higher in MM
patients (16.7%) than in lymphoma patients (5.4%). However,
the difference was not statistically significance. Given that
the number of patients who were analyzed to determine the
disappearance rate of anti-HBc during chemotherapy was
small (18 MM and 37 lymphoma), we could not conclude
whether or not MM patients experience a higher disappear-
ance rate of anti-HBc during chemotherapy than lymphoma
patients. Nevertheless, since MM is an incurable disease by
nature of dysfunctional humoral immunity, we suspect that
MM patients are at a high risk of anti-HBc disappearance.
Meanwhile, our study also found that reversion of anti-HBs
occurs more frequently in MM patients than in lymphoma
Hyunsung Park, HBV-Related Hepatitis after ASCT
Table 3.  Disappearance of antibody during chemotherapy prior to ASCT in patients who were positive for anti-HBc or anti-
HBs at the time of diagnosis of MM or lymphoma
Positive at diagnosis Negative at ASCT Positive at ASCT p-value 
Anti-HBc
MM (n=18) 3 (16.7) 15 (83.3) 0.317
Lymphoma (n=37) 2 (5.4) 35 (94.6)
Rituximaba) (n=18) 2 (11.1) 16 (88.9) 0.230
No rituximabb) (n=19) 0 ( 19 (100)
Anti-HBs
MM (n=32) 8 (25.0) 24 (75.0) 0.002
Lymphoma (n=96) 4 (4.2) 92 (95.8)
Rituximaba) (n=46) 3 (6.5) 43 (93.5) 0.347
No rituximabb) (n=50) 1 (2.0) 49 (98.0)
Values are presented as number (%). ASCT, autologous stem cell transplantation; Anti-HBc, hepatitis B core antibody; Anti-
HBs, hepatitis B surface antibody; MM, multiple myeloma. a)Patients receiving rituximab-containing chemotherapy for lym-
phoma before ASCT, b)Patients receiving chemotherapy without rituximab for lymphoma before ASCT.
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patients during chemotherapy. In addition, HBV-related
hepatitis developed more frequently in MM patients. Similar
to these findings, both loss of anti-HBs and MM were 
reported as independent risk factors for HBV reactivation
previously [19,20]. Therefore, we recommend that MM
HBsAg-negative, anti-HBc–negative patients should be care-
fully evaluated for the risk of HBV-related hepatitis during
chemotherapy.
Rituximab is a chimeric anti-CD20 monoclonal antibody
that is extensively used in various B-cell lymphoid malignan-
cies and immune-mediated diseases [21]. Although ritux-
imab-based treatments are known to reduce the levels of
circulating antibodies [22], we did not find significantly 
increased disappearance rates of anti-HBc or anti-HBs in
lymphoma patients who received a rituximab-containing
chemotherapy as induction chemotherapy. In addition, none
of those receiving rituximab-containing induction chemo-
therapy showed HBV-related hepatitis after ASCT. However,
the small number of patients limited our ability to reach a
definitive conclusion.
This study has a few limitations. First, HBV serology was
tested in accordance with clinical suspicions, which could 
introduce potential bias. Second, as HBV-DNA levels were
not tested regularly, we could not identify the appearance of
HBV-DNA in the serum (e.g., HBV reactivation) in the 
absence of HBsAg. Therefore, the rate of HBV reactivation
may have consequently been underestimated, especially in
patients who had treated with rituximab which is one of the
major risk factors of HBV reactivation [11]. Because it is not
necessary to conduct anti-HBV treatments in patients who
have only positive findings of HBV-DNA without elevation
of biochemical markers for hepatitis, the determination of the
patients with HBV-related hepatitis may be useful in clinical
practice. Third, vaccination history could not be obtained.
Considering that universal vaccination of all infants has been
performed since 1991 in Korea [23], the possibility of aggres-
sive vaccination, which may reduce the rate of HBV-related
hepatitis, could not be excluded. Finally, due to the retro-
spective nature of this study, only a small number of patients
had results on anti-HBc or anti-HBs at the time of diagnosis
of MM or lymphoma. As only one of three patients who were
anti-HBc–negative at baseline and experienced HBsAg rever-
sion after ASCT was identified to have anti-HBc at the time
of diagnosis, our study had insufficient data with which to
reveal an association between disappearance of anti-HBc and
HBV-related hepatitis. Despite these limitations, our study
demonstrates for the first time the potential risk of anti-HBc
disappearance and HBV-related hepatitis in MM and lym-
phoma patients. Larger, prospective studies are needed to
confirm the results of our study.
In summary, our study showed that 16.7% of MM patients
and 5.4% of lymphoma patients who were HBsAg-negative
and anti-HBc–positive at the time of diagnosis of MM or lym-
phoma had lost their anti-HBc positivity during chemother-
apy prior to ASCT and remained at risk of HBV-related
hepatitis. Hence, patients who are HBsAg-negative and anti-
HBc–negative at the time of ASCT should also be considered
at risk of HBV-related hepatitis, particularly MM patients in
HBV endemic areas. Not only screening tests for HBV sero-
logic markers and HBV-DNA levels at the time of ASCT but
also a comprehensive review of previous HBV history, 
including serologic markers and HBV-DNA, may necessary
to determine which patients are at risk of HBV-related hep-
atitis after ASCT.
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